<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Natriuretic peptide measurement in non-heart failure settings
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Natriuretic peptide measurement in non-heart failure settings
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Natriuretic peptide measurement in non-heart failure settings
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Horng H Chen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wilson S Colucci, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen S Gottlieb, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allan S Jaffe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H27656580">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natriuretic peptide system impacts salt and water handling and pressure regulation and may influence myocardial structure and function.
        </p>
        <p>
         B-type natriuretic peptide (BNP) is a natriuretic hormone initially identified in the brain but released primarily from the heart, particularly the ventricles. Cleavage of the prohormone pro-BNP produces biologically active 32 amino acid BNP as well as biologically inert 76 amino acid N-terminal pro-BNP (NT-proBNP).
        </p>
        <p>
         Atrial natriuretic peptide (ANP) is a hormone that is released from myocardial cells in the atria and, in some cases, the ventricles in response to volume expansion and possibly increased wall stress [
         <a href="#rid1">
          1
         </a>
         ]. ANP circulates primarily as a 28 amino acid polypeptide, consisting of amino acids 99 to 126 from the C-terminal end of its prohormone, pro-ANP.
        </p>
        <p>
         The release of both ANP and BNP is increased in heart failure (HF), as ventricular cells are recruited to secrete both ANP and BNP in response to the high ventricular filling pressures [
         <a href="#rid2">
          2
         </a>
         ]. The plasma concentrations of both hormones are increased in patients with asymptomatic and symptomatic left ventricular dysfunction, permitting their use in diagnosis (
         <a class="graphic graphic_figure graphicRef55557" href="/z/d/graphic/55557.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Natriuretic peptide levels are elevated in some patients with coronary heart disease, valvular heart disease, constrictive pericarditis, pulmonary hypertension, and sepsis (
         <a class="graphic graphic_table graphicRef99857" href="/z/d/graphic/99857.html" rel="external">
          table 1
         </a>
         ). The diagnostic and prognostic value of measuring plasma BNP and NT-proBNP in asymptomatic individuals and patients with such non-HF conditions is discussed here. While the discussion here will focus on patients without overt HF, BNP or NT-proBNP elevations in some of these settings may be a sign of undiagnosed HF.
        </p>
        <p>
         The diagnostic and prognostic value of measuring plasma BNP, NT-proBNP, and midregional pro-ANP in patients with HF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27939568">
         <span class="h1">
          ASSAY INTERPRETATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of variables affect plasma B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels, including the assay used, age (higher normal values with age), sex (higher values in women), body mass index (lower levels with higher body mass index), and genetic factors. In addition, there is intraindividual and analytic assay variation. These issues are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure", section on 'Assay interpretation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure", section on 'Age, sex, and body mass'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27939639">
         <span class="h1">
          CONDITIONS
         </span>
        </p>
        <p class="headingAnchor" id="H27939351">
         <span class="h2">
          Renal failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) concentrations are elevated in patients with renal failure. In patients with chronic kidney disease, decreased estimated glomerular filtration rate is associated with increased plasma BNP and even greater elevation in NT-proBNP concentrations. This issue is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure", section on 'Renal failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27656787">
         <span class="h2">
          Predictor of cardiovascular events
         </span>
        </p>
        <p class="headingAnchor" id="H18422045">
         <span class="h3">
          Population-based studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma BNP and the N-terminal fragment of pro-atrial natriuretic peptide (NT-proANP) levels are predictors of the development of HF, as well as other cardiovascular events, in asymptomatic patients without HF. This was demonstrated in a prospective evaluation of 3346 participants (mean age 59 years) in the Framingham Heart Study [
         <a href="#rid3">
          3
         </a>
         ]. At five years, 119 patients died (3.6 percent) and 79 had a first cardiovascular event (myocardial infarction [MI], coronary insufficiency, death from coronary heart disease, HF, or stroke; 2.4 percent). Baseline plasma BNP and NT-proANP levels above the 80
         <sup>
          th
         </sup>
         percentile were both associated with a significant increase in the subsequent development of HF (adjusted hazard ratio [HR] 3.07 and 5.02), as well as less marked increases in all-cause mortality, atrial fibrillation, and stroke or transient ischemic attack.
        </p>
        <p>
         The ability of NT-proBNP to predict cardiovascular events was evaluated in a population-based study of 626 older adults [
         <a href="#rid4">
          4
         </a>
         ]. Individuals with NT-proBNP levels above the 80
         <sup>
          th
         </sup>
         percentile (more than 655 pg/mL) had, at five-year follow-up, a significant increase in mortality compared with those with lower values (adjusted HR for mortality 1.96 overall and 1.82 after adjustment for left ventricular dysfunction, and an absolute unadjusted increase in mortality of 24.5 percent). Among the 537 participants with no prior history of cardiovascular disease, those with NT-proBNP above the 80
         <sup>
          th
         </sup>
         percentile had a significantly higher risk of a first major cardiovascular event (adjusted HR 3.24).
        </p>
        <p class="headingAnchor" id="H27656794">
         <span class="h3">
          Prognosis in ACS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevations in plasma BNP or NT-proBNP are associated with increased mortality in patients with an acute coronary syndrome (ACS). The prognostic value of plasma BNP and NT-proBNP in this setting is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/77.html" rel="external">
          "Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes", section on 'BNP and NT-proBNP'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27656801">
         <span class="h3">
          Prognosis in stable angina
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma BNP concentrations have prognostic value in patients with stable angina [
         <a href="#rid5">
          5,6
         </a>
         ]. The magnitude of this effect was illustrated in a review of 1085 such patients who had plasma BNP measured at baseline and were then prospectively followed for a mean of 2.5 years [
         <a href="#rid6">
          6
         </a>
         ]. There was a stepwise decrease in event-free survival across quartiles of plasma BNP. After adjustment for confounders including left ventricular ejection fraction (LVEF), patients in the highest quartile (plasma BNP &gt;100 pg/mL) had a significant 6.1-fold increase in risk compared with those in the lowest quartile (plasma BNP &lt;12 pg/mL); the HR was 4.4 for plasma BNP values &gt;100 pg/mL.
        </p>
        <p>
         Plasma NT-proBNP appears to have equivalent predictive value in these patients [
         <a href="#rid5">
          5
         </a>
         ]. The predictive value of NT-proBNP in patients with stable angina was evaluated in a report of 1034 patients who were referred for coronary angiography and then followed for nine years [
         <a href="#rid7">
          7
         </a>
         ]. At follow-up, 288 patients (28 percent) had died. The patients who died had significantly higher NT-proBNP values at presentation (386 versus 120 pg/mL). Patients with NT-proBNP values in the highest quartile were older, had a lower LVEF, and were more likely to have diabetes and a prior MI. In a multivariable model, these patients had an HR for death of 2.4 compared with those in the lowest quartile.
        </p>
        <p>
         Similar findings were noted in a review of 1059 patients with chronic stable angina [
         <a href="#rid8">
          8
         </a>
         ]. At a median of 3.6 years, the five-year mortality progressively increased from 4.7 percent in patients in the lowest quartile of NT-proBNP to 7.8 percent, 11.4 percent, and 32.7 percent in the second, third, and highest quintiles, respectively (adjusted HR 6.0, 95% CI 1.6-23 for the highest compared with lowest quintile). A similar prognostic value was noted for cardiovascular mortality (
         <a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">
          table 2
         </a>
         ). However, as in the previous study, patients in the highest NT-proBNP quartile had other major comorbidities including highest rates of diabetes, atrial fibrillation, and New York Heart Association class III or IV (18.5 versus 0.8 percent in the lowest quartile).
        </p>
        <p>
         Further studies are required to determine if measurement of BNP or NT-proBNP has clinical utility in the management of patients with stable angina.
        </p>
        <p class="headingAnchor" id="H18422007">
         <span class="h3">
          Postoperative complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pre- and postoperative elevations in plasma BNP are associated with an increased risk of adverse cardiovascular events at 30 days. In a 2009 meta-analysis that included seven studies of 2841 patients who had a serum BNP measurement before noncardiac surgery, there was a statistically significant association between a preoperative elevation in serum BNP and the cardiovascular outcomes of death, cardiac death, and nonfatal MI at 30 days (adjusted odds ratio [OR] 19.3) [
         <a href="#rid9">
          9
         </a>
         ]. A 2011 meta-analysis that evaluated postoperative mortality at six months or later came to a similar conclusion [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The relationship between pre- and postoperative natriuretic peptide
         <strong>
         </strong>
         levels and cardiovascular outcomes was evaluated in a meta-analysis of 18 studies (n = 2179) in which natriuretic peptide
         <strong>
         </strong>
         was sampled preoperatively and within seven days after surgery [
         <a href="#rid11">
          11
         </a>
         ]. An elevated preoperative natriuretic peptide level (&gt;92 ng/L for BNP or &gt;300 ng/L for NT-proBNP) predicted the primary composite outcome of death or nonfatal MI at 30 days (OR 3.4) and at ≥180 days (OR 2.6). The addition of postoperative natriuretic peptide
         <strong>
         </strong>
         to a risk-prediction model containing preoperative natriuretic peptide
         <strong>
         </strong>
         improved risk classification at 30 and ≥180 days. Elevated postoperative natriuretic peptide
         <strong>
         </strong>
         was the strongest independent predictor of the primary outcome at both time points. While it appears that natriuretic peptide
         <strong>
         </strong>
         measured either before or shortly after surgery has prognostic information, the implications of this finding are uncertain.
        </p>
        <p class="headingAnchor" id="H16051290">
         <span class="h2">
          Valvular heart disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential prognostic value of natriuretic peptide measurement in patients with valvular heart disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8114.html" rel="external">
          "Clinical manifestations and diagnosis of low gradient severe aortic stenosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8132.html" rel="external">
          "Chronic primary mitral regurgitation: General management", section on 'Natriuretic peptide levels'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27657164">
         <span class="h2">
          Constrictive pericarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemodynamic assessment is often required to distinguish constrictive pericarditis from restrictive cardiomyopathy. However, wall stretch is increased in the latter but minimized in the former by the thickened pericardium. This difference suggests that measurement of plasma BNP might have value in distinguishing between these two disorders.
        </p>
        <p>
         This hypothesis was evaluated in a report of six patients with constrictive pericarditis and five with restrictive cardiomyopathy in which plasma BNP was markedly elevated in patients with restrictive cardiomyopathy but just above normal in those with constrictive pericarditis (825 versus 128 pg/mL) [
         <a href="#rid12">
          12
         </a>
         ]. These intriguing observations need to be confirmed in a larger number of patients to determine the accuracy of BNP testing in this setting. (See
         <a class="medical medical_review" href="/z/d/html/4946.html" rel="external">
          "Differentiating constrictive pericarditis and restrictive cardiomyopathy", section on 'Plasma BNP'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27657061">
         <span class="h2">
          Pulmonary hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma BNP concentrations are elevated in patients with primary or secondary pulmonary hypertension. In such patients, they correlate positively with right atrial pressure, mean pulmonary artery pressure, pulmonary vascular resistance, and right ventricular mass, and inversely with cardiac index [
         <a href="#rid13">
          13,14
         </a>
         ]. Using elevated plasma BNP to determine the cause of dyspnea in patients with pulmonary hypertension may be misleading since lung disease is responsible for the dyspnea unless the patient has secondary pulmonary hypertension due to left heart disease. (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27657068">
         <span class="h2">
          Sepsis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The data supporting the diagnostic accuracy of natriuretic peptides are largely derived from emergency department patients. The role of BNP and NT-proBNP in other settings, in particular the intensive care unit (ICU), is less well established.
        </p>
        <p>
         An observational series from a single center suggests that in an ICU setting, patients with a diagnosis of sepsis are as likely to have elevated BNP and NT-proBNP levels as patients with decompensated HF [
         <a href="#rid15">
          15
         </a>
         ]. Among 249 consecutive patients, 24 were diagnosed with sepsis and 51 with decompensated HF. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BNP and NT-proBNP levels were similar in both groups (572 versus 581 ng/L and 6526 versus 4300 ng/L for sepsis and HF patients, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with decompensated HF had a significantly higher mean pulmonary artery capillary wedge pressure (22 versus 16 mmHg) and a lower mean cardiac index (2.2 versus 4.6 L/min per m
         <sup>
          2
         </sup>
         ).
        </p>
        <p>
        </p>
        <p>
         Thus, in a heterogeneous population of critically ill patients, levels of natriuretic peptides were similar in patients with sepsis and those with decompensated HF.
        </p>
        <p class="headingAnchor" id="H3319980180">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115814.html" rel="external">
          "Society guideline links: Perioperative cardiovascular evaluation and management"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">
          "Society guideline links: Cardiac valve disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1540166577">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels (NT-proBNP) are elevated in patients with heart failure (HF) as well as in some patients without overt HF with a variety of conditions including renal failure, coronary heart disease, valvular heart disease, restrictive cardiomyopathy, pulmonary hypertension, and sepsis (
         <a class="graphic graphic_table graphicRef99857" href="/z/d/graphic/99857.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated BNP or NT-proBNP levels predict an increased risk of cardiovascular events in various patient populations, including those with and without prior symptomatic cardiovascular disease. (See
         <a class="local">
          'Predictor of cardiovascular events'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kragelund C, Grønning B, Køber L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ndrepepa G, Braun S, Niemöller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 2005; 112:2102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009; 54:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lurati Buse GA, Koller MT, Burkhart C, et al. The predictive value of preoperative natriuretic peptide concentrations in adults undergoing surgery: a systematic review and meta-analysis. Anesth Analg 2011; 112:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodseth RN, Biccard BM, Le Manach Y, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol 2014; 63:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005; 45:1900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudiger A, Gasser S, Fischler M, et al. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34:2140.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 17124 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16487838" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8477647" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14960742" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15811980" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16386664" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16458135" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15716560" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16186420" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19833258" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21372274" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The predictive value of preoperative natriuretic peptide concentrations in adults undergoing surgery: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24076282" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936624" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9426041" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14998614" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16763507" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
